

Hyoscine butylbromide for colorectal polyp detection: prospective, randomized, placebo-controlled trial

Carlos Eduardo Oliveira dos Santos,^{1,*} Hamilton Moreira,¹ Julio Carlos Pereira-Lima,¹ Carmen Australia Paredes Marcondes Ribas,¹ Fernanda de Quadros Onófrio,¹ Alexandre Eduardo Augusti Czecko,¹ Rafael Koerich Ramos,¹ Caroline Aragão de Carvalho¹

¹Departamento de Endoscopia e Gastroenterologia, Santa Casa de Caridade, Bage, RS, BR. ²Programa de Pós-graduação em Princípios de Cirurgia, Faculdade Evangélica do Paraná, Curitiba, PR, BR. ³Departamento de Gastroenterologia e Endoscopia, Hospital Santa Casa, Porto Alegre, RS, BR.

OBJECTIVES: The removal of pre-malignant colorectal lesions prevents cancer. Hyoscine has been proposed as a means of improving diagnosis by reducing colonic movements. The aim of this study was to analyze whether this anti-spasmodic enhances the detection of pre-malignant colorectal lesions.

METHODS: In a randomized, double-blinded fashion patients received hyoscine or a saline solution in all consecutive colonoscopies in which the cecum was reached. Lesions were analysed with respect to number, size, location, histology and capillary pattern.

RESULTS: A total of 440 colonoscopies were randomized. The overall polyp detection rate (PDR) and the adenoma detection rate (ADR) were 65.2% and 49.3%, respectively. In the hyoscine group, non-polypoid lesions were detected significantly more often ($p=0.01$). In the placebo group 281 lesions were diagnosed (202 adenomas) and in the hyoscine group 282 lesions were detected (189 adenomas) ($p=0.23$). The PDR and ADR were similar between the placebo and hyoscine groups (64% vs 66% and 50% vs 47%, respectively). No differences were observed between the two groups in the advanced-ADR or advanced neoplasia detection rate, as well the mean numbers of polyps, adenomas, advanced adenomas and advanced neoplasias detected per patient. The administration of hyoscine also did not improve the diagnostic accuracy of digital chromoendoscopy. The presence of adenomatous polyps in the right colon was detected significantly more frequently in the hyoscine group (OR 5.41 95% CI 2.7 - 11; $p<0.01$ vs OR 2.3 95% CI 1.1 - 4.6; $p=0.02$).

CONCLUSION: The use of hyoscine before beginning the withdrawal of the colonoscope does not seem to enhance the PDR and the ADR.

KEYWORDS: Colonoscopy; Adenoma; Colonic Polyps; Scopolamine Hydrobromide.

Santos CE, Moreira H, Pereira-Lima JC, Ribas CA, Onófrio FQ, Czecko AE, et al. Hyoscine butylbromide for colorectal polyp detection: prospective, randomized, placebo-controlled trial. Clinics. 2017;72(7):395-399

Received for publication on September 30, 2016; First review completed on November 29, 2016; Accepted for publication on January 13, 2017

*Corresponding author. E-mail: ddendo@uol.com.br

INTRODUCTION

Colorectal cancer (CRC) represents one of the leading causes of cancer-related deaths worldwide. The diagnosis of pre-malignant lesions, and the subsequent removal of such lesions is a well-recognized strategy in the secondary prevention of CRC (1). Colonoscopy is considered the gold standard in achieving this goal, with the adenoma detection rate (ADR) (defined as the index of procedures in which at least one adenoma is diagnosed) considered a known indicator of the quality of the method (2). Nevertheless, a considerable number of adenomas are missed (3,4), which are related to

interval cancer, especially in the right colon (5). Interval cancer in the right colon could be partially explained by the non-diagnosis of non-polypoid lesions, since these neoplasms are more common in the right colon and are more aggressive (6).

Many factors could contribute to the failure to diagnose these lesions, including inadequate bowel preparation (7,8), colonoscopy technique (9), colonoscope withdrawal time (10) and polyp location (11,12). New techniques have been developed to increase the ADR, such as high-definition colonoscopes (13), chromoendoscopy (14), G-EYE colonoscope (15), the Third Eye colonoscope (16), full spectrum endoscopy (17), water-immersion colonoscopy (18), retroflexion in the right colon (19), cap-assisted colonoscopy (20), endocuff-assisted colonoscopy (21), and endorings (22).

It has been suggested that colonic peristalsis may hinder the analysis of the mucosal surface, and consequently the discovery of colonic lesions.

Hyoscine is a spasmolytic agent of the gastrointestinal tract. The peripheral anticholinergic action of hyoscine results from the blockade of the intramural ganglia of hollow viscera, as

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

DOI: 10.6061/clinics/2017/07/01



well as an anti-muscarinic activity. The antiperistaltic effect of this compound on the small intestine was demonstrated by Gutzeit et al. (23), with an average onset of action at 85 seconds after intravenous infusion and an average duration of 21 minutes. The administration of hyoscine during colonoscopy could be an alternative in controlling colonic contractility and could in this way facilitate the detection and characterization of colonic lesions. However, anti-spasmodic agents such as glucagon (24) and atropine (25) have not shown benefits in this setting. Hyoscine is inexpensive, widely available and safe. Furthermore, there have been no studies to date evaluating the use of spasmolytic agents in the differential diagnosis of colorectal lesions by digital chromoendoscopy. It was hypothesized that the analysis of the capillary pattern of colorectal lesions would be facilitated under the effect of hyoscine, which decreases the peristaltic movements of the colon.

The goal of this prospective, randomized, placebo-controlled double-blinded trial was to analyse whether the use of hyoscine enhances the detection of polyps and adenomas. As a secondary objective, this study aimed to evaluate whether this drug has any impact on the differential diagnosis of colorectal lesions during colonoscopy with magnification and digital chromoscopy.

METHODS

The participating institutions were as follows: Santa Casa de Caridade de Bagé, RS; Evangelic Faculty of Parana, Curitiba, PR; and Santa Casa Hospital, Porto Alegre, RS. The study was approved by the Ethics Committee of Santa Casa de Caridade, Bagé, RS and was conducted according to the Declaration of Helsinki. Informed written consent (26) was obtained from all participants.

Patients who were referred to our endoscopy unit for CRC screening, surveillance or a clinical suspicion of CRC were randomly assigned to receive 20mg of hyoscine (Buscopan, Boehringer Ingelheim of Brazil Quim. e Farm. Ltda, Itapeverica da Serra, Brazil) or placebo (saline solution) as soon as the colonoscope reached the cecum. The randomization was generated by the www.researchrandomizer.org site. Sealed envelopes were opened by the nurse taking care of the patient's sedation. The endoscopist was blinded to the randomization. The exclusion criteria were as follows: inadequate bowel preparation, incomplete colonoscopy, inflammatory bowel disease, advanced cancer, prior colorectal surgery, reported or known allergy to hyoscine, and patients referred to polypectomy or endoscopic mucosal resection due to previously diagnosed lesions.

Between March and July 2015, 517 consecutively performed colonoscopies were analysed for inclusion in the study. A total of 77 cases were excluded: 20 had previously diagnosed colon lesions and were referred for colonoscopic removal; 13 had previously undergone colon resection surgery; 11 had inadequate bowel preparation; 7 had advanced carcinomas; 7 were aged less than 30 years; 7 being allergic to hyoscine and in 2 cases the cecum was not reached. Therefore, 440 cases were randomized, with 220 cases in each arm. The patients were analysed with respect to age, gender, colonoscope withdrawal time, endoscopic findings and histopathology.

Procedures

Bowel preparation was undergone with a clear liquids diet on the day prior to the procedure and 1000 ml of a 10%

mannitol solution on the day of lower endoscopy. All colonoscopies were performed under conscious sedation with midazolam and fentanyl.

One millilitre of hyoscine (20 mg) or placebo was infused intravenously as soon as the cecum was reached during colonoscopy (Fujinon 590ZW5 with high resolution and magnification, Fujifilm Corp., Saitama, Japan) with the EPX4400 processor. We waited for at least one minute before starting withdrawal, of the colonoscope because the antispasmodic effect begins within one minute and lasts for 10-15 minutes (27).

All procedures were performed by one of the authors (CEOS) who had already performed more than 12,000 colonoscopies with magnification and real or digital chromoendoscopy.

The colonoscope withdrawal time was defined as the time spent between cecum examination after the intravenous administration of the drug or placebo and the removal of the colonoscope through the anus. In all cases, this procedure lasted more than 6 minutes.

Patients were monitored continuously during the examination by means of a pulse oximeter. The alarm remained off during the colonoscopies and the monitor was seen only by the nurse and not by the endoscopist. To maintain patient safety, the nurse was instructed to communicate with the endoscopist in case of significant tachycardia, which was considered relevant when the heart beat rate was greater than 140/minute for more than 30 seconds (28).

Lesions characteristics

The lesion size was estimated with an open biopsy forceps (7mm). The lesions morphology was determined according to the Paris classification (29), in which non-polypoid lesions are considered those less than 2.5mm in height, which was estimated with a closed biopsy forceps touching the lateral margins of the lesion, (types 0-IIa, 0-IIa + IIc, 0-IIc + IIa, 0-IIc, and 0-IIb and laterally spreading tumors - LSTs). Polypoid lesions are those greater than 2.5mm in height (types 0-Is, 0-Isp, and 0-Ip). All lesions included in the study had the endoscopic appearance of lesions known as superficial lesions, limited to the mucosa or submucosa, according to Kudo (30). The right colon was considered the cecum, and the ascending and transverse colon, while the left colon was the rectum, the sigmoid and the descending colon.

All lesions were evaluated using digital chromoendoscopy (Flexible Spectral Imaging Color Enhancement – FICE) to analyse capillary patterns for the real time differential diagnosis between neoplastic and non-neoplastic lesions.

According to the Teixeira Classification (31), lesions with I-II patterns were considered non-neoplastic, and lesions with III-V patterns were considered neoplastic. Non-neoplastic lesions were hyperplastic and inflammatory polyps, and neoplastic lesions were tubular, tubulovillous, villous, sessile serrated, and traditional serrated adenomas and early carcinomas. Those lesions greater than 1 cm, with villous histology or high-grade dysplasia were considered advanced adenomas. Advanced neoplasias were the advanced adenomas and early carcinomas.

All the lesions were removed endoscopically and were analysed by the same pathologist who was blinded to the endoscopic diagnosis.

Statistical Analysis

The data were inserted into the Stata software version 11.2. Categorical variables were described using absolute and



relative frequencies. Numerical variables were described as the mean and standard deviation (SD) when the distribution of the data was normal or as the median and interquartile interval when their distribution was not normal.

Bivariate analyses of the categorical variables comparing the hyoscine and placebo groups were performed using Fisher's exact test. Bivariate analyses of numerical variables comparing the groups with and without hyoscine were performed using a t-test (when comparing means) or the Mann-Whitney U test (when medians were compared).

A logistic regression was used to analyse the adenoma detection rate (ADR) with the odds ratio (OR) and confidence interval (95% CI). For the sample size calculation, the analysis of the detection rate of adenomas was considered as an outcome, stratified according to the treatment group (hyoscine) and control group (placebo). The parameters considered were as follows: power of 80%, alpha-error of 5%, prevalence of 50% outcome, 10-75% exposure frequency and relative risk of at least 1.7 or an odds ratios of 2.6 between exposed *versus* unexposed, resulting in a patient number of 216.

The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the capillary pattern analysis were reported. The significance level adopted was 5% for the bicaudal tests.

RESULTS

From a total of 517 consecutive patients, 77 (14.9%) did not meet the inclusion criteria. Therefore, 220 patients were randomized to the hyoscine group, and the other 220 were included in the placebo group. A total of 563 lesions were diagnosed in 287 colonoscopies (65.2%), with 391 adenomas in 217 patients (49.3%). These figures are described in Table 1.

Sex, age, mean lesion size (4.9 mm + /- 4.2 *vs* 5.3 mm + /- 6.2, $p=0.46$), and mean colonoscope withdrawal time (9.8 min + /- 5.7 *vs* 9.8 min + /- 8.3, $p=0.99$) were similar between the two groups. However, the median and the interquartile interval were higher in the placebo group with respect to the colonoscope withdrawal time [7.7 min (7.1-9.8) *vs* 7.5 min (6.8-8.6), $p=0.05$].

In the hyoscine group, significantly more non-polypoid lesions were detected than in the placebo group (79.8% *vs* 69.4%); nevertheless, polypoid lesions composed 20.2% of the lesions in the hyoscine group and 30.6% in the placebo group ($p=0.01$). The proportion of adenomas and non-polypoid adenomas found in the right colon was similar between the two groups.

Analysing the lesions via digital chromoendoscopy in the placebo group, the accuracy was 94.3%, the sensitivity 94.1%, the specificity 94.7%, the PPV 98% and the NPV 85.7%, while these values were 95%, 93.7%, 97.8%, 98.9% and 88.1%, respectively, in the hyoscine group (Table 2, all these data were not significantly different).

The detection of advanced adenomas (12.7% *vs* 11.8%) and advanced neoplasias (13.6% *vs* 12.3%), the PDR (64.6% *vs* 65.9%) and the ADR (50.5% *vs* 46.8%) were also similar between the placebo and the hyoscine groups, respectively (Table 1), as well as the mean number of polyps (1.3 *vs* 1.3), adenomas (0.92 *vs* 0.86), advanced adenomas (0.16 *vs* 0.18) and advanced neoplasias (0.16 *vs* 0.18) detected per patient ($p=0.97$).

The logistic regression analysis demonstrated that 1 additional minute of colonoscope withdrawal time and the presence of one more lesion were associated with the detection of one more adenoma in the placebo group, and

Table 1 - Patient and lesion characteristics.

Variable	Placebo group (%)	Hyoscine group (%)	p value*
	N=220 patients	N=220 patients	
Sex			0.76
Female	151 (68.6)	147 (66.8)	
Male	69 (31.4)	73 (33.2)	
Age (years)			0.50
< 50	47 (21.4)	54 (24.6)	
≥ 50	173 (78.6)	166 (75.4)	
Lesions per patient			0.65
0	78 (35.4)	75 (34.0)	
1	68 (30.9)	71 (32.3)	
2	38 (17.3)	42 (19.1)	
3	24 (10.9)	16 (7.3)	
≥ 4	12 (5.5)	16 (7.3)	
Size (mm)	N= 281 lesions	N=282 lesions	1.00
< 10	262 (93.2)	262 (92.9)	
≥ 10	19 (6.8)	20 (7.1)	
Morphology			0.01
Non-polypoid	195 (69.4)	225 (79.8)	
Polypoid	86 (30.6)	57 (20.2)	
Capillary pattern			0.15
Non-neoplastic	84 (29.9)	101 (35.8)	
Neoplastic	197 (70.1)	181 (64.2)	
Pathology			0.20
Non-neoplastic	76 (27.1)	91 (32.3)	
Neoplastic	205 (72.9)	191 (67.7)	
Adenomas			0.23
No	79 (28.1)	93 (33.0)	
Yes	202 (71.9)	189 (67.0)	
Advanced adenoma			0.62
No	247 (87.9)	243 (86.2)	
Yes	34 (12.1)	39 (13.8)	
Advanced neoplasia			0.71
No	245 (87.2)	242 (85.2)	
Yes	36 (12.8)	40 (14.8)	
Advanced histology			0.45
No	265 (94.3)	270 (95.7)	
Yes	16 (5.7)	12 (4.3)	
Location			0.18
Right Colon	152 (54.1)	136 (48.2)	
Left Colon	129 (45.9)	146 (51.8)	

Table 2 - Diagnostic criteria of the lesions using digital chromoendoscopy.

	Placebo group (n=281)	Hyoscine group (n=282)
Sensitivity (%)	94.1 (90.0 - 95.9)	93.7 (89.3 - 95.7)
Specificity (%)	94.7 (87.1 - 98.5)	97.8 (92.3 - 99.7)
PPV (%)	98.0 (94.9 - 99.4)	98.9 (96.1 - 99.9)
NPV (%)	85.7 (76.4 - 92.4)	88.1 (80.2 - 93.7)
Accuracy (%)	94.3	95
Kappa	0.86 (0.79 - 0.93)	0.89 (0.83 - 0.95)

the presence of a lesion in the right colon was associated with the detection of more lesions in the hyoscine group.

Polypoid lesions were a risk factor for adenoma only in the placebo group. The complete logistic regression analysis is depicted in Table 3.

No serious side effects were observed in the study groups. Three patients presented with significant tachycardia lasting less than 30 seconds in the hyoscine group.

DISCUSSION

We hypothesized that the spasmolytic action of hyoscine would favour a greater detection of polyps and adenomas,

**Table 3** - Logistic regression analysis of the adenoma detection rate.

Variable	Placebo group		Hyoscine group	
	OR IC95%	p value	OR IC95%	p value
Male sex	1.4 (0.8-2.4)	0.3	1.2 (0.7-2.2)	0.5
≥50 years	2.8 (1.4-5.5)	<0.01	2.4 (1.3-4.6)	0.01
Lesions (number)	24 (19-60)	<0.01	7 (4.2-12)	<0.01
Polypoid lesions	8.3 (1.9-35)	<0.01	1.7 (0.7-3.7)	0.2
Right colon	1.8 (0.9-3.7)	0.1	5.8 (2.8-12)	<0.01
Time (min)	3.6 (2.4-5.4)	<0.01	2.0 (1.5-2.5)	<0.01

thus increasing the ADR. Other studies have suggested that the administration of a spasmolytic drug could also facilitate the insertion of the colonoscope to the cecum (32,33) or could improve the visualization of the colonic surface due to the reduction of spasms and the flattening of the colonic haustrations (34). However, these results were not reproduced by other authors (35,36).

Employing a grading scale for colonic spasms, Lee et al. (37) observed a significant decrease in the number of spasms between colonoscope insertion and withdrawal in patients receiving hyoscine in comparison to those receiving placebo. However, this group did not show any difference in the number of polyps per patient or the ADR. Nonetheless, Lee et al. found a trend for a higher polyp detection rate in the hyoscine group when comparing a subgroup of placebo patients with severe spasms. Our study did not show an advantage to injecting hyoscine when the colonoscope reached the cecum in terms of the PDR or ADR, which is in line with two recently published meta-analyses (38,39). There was also no diagnostic advantage either in the detection of advanced adenomas, or advanced neoplasias.

In a study of 601 patients, Corte et al. (40) identified a higher polyp rate per patient in a hyoscine group than in a placebo group (0.91 vs 0.7 $p=0.04$), but the PDR and ADR were similar for both arms (43.6 vs 36.6% and 27.1% vs 21.8%, respectively). In a study by de Brouwer et al. (41), there was no difference in the PDR, ADR or mean number of polyps detected per patient, in an Italian double-blind, randomized trial comparing hyoscine and placebo (28).

The present study also did not demonstrate any difference in the PDR, ADR, or mean number of detected polyps or adenomas per patient when comparing hyoscine with placebo.

In contrast to the findings of Rondonotti et al. (28), who encountered significantly fewer non-polypoid colorectal lesions in the hyoscine group, we found significantly more non-polypoid colorectal lesions in the hyoscine arm. Our findings refute the hypothesis that spasmolytic agents would hinder the identification of flat lesions by stretching of the colon. However, de Brouwer et al. (41) identified no difference in the morphology of the diagnosed colorectal lesions, when comparing hyoscine and placebo.

We observed a longer withdrawal time in the placebo group, which in our study, was associated with the ADR according to the logistic regression analysis. In contrast, in the hyoscine group, the main factor associated with the ADR was the detection of a lesion in the right colon. These figures are comparable to those reported by Corte et al. (40). Perhaps this longer withdrawal time in the placebo group can be explained by waiting for the colonic spasms to end during the examination.

The analysis of the capillary pattern by magnification colonoscopy with digital chromoscopy has yielded excellent results in the differential diagnosis of neoplastic and non-neoplastic colorectal lesions, with good to excellent intra- and interobserver agreement (42-45). We also hypothesized that the abolishment of colonic contractility would allow a better evaluation of these lesions by digital chromoendoscopy with magnification. However, no differences regarding the diagnostic sensitivity, specificity, PPV, NPV or accuracy were observed when comparing patients who received placebo or hyoscine. Perhaps, the use of hyoscine could improve the discrimination between neoplastic and non-neoplastic colorectal lesions, and improve the PDR and ADR among beginners, but not after the acquisition of expertise. Indeed, one of the limitations of this study is that all the examinations were performed by a single endoscopist, who is very familiar with the Japanese Classification of Colorectal Carcinoma (46), which may explain the large number of lesions morphologically classified as NPLs.

In summary, we found a higher number of non-polypoid lesions in the hyoscine group and more polypoid lesions in the placebo group, but with no difference with respect to the colonic segment (left or right). This double-blind, prospective, placebo-controlled trial did not show any evidence supporting the routine use of hyoscine during colonoscopy to improve the PDR and ADR or to augment the diagnosis of advanced adenomas or advanced neoplasias. We could also not demonstrate an impact of the drug in differentiating neoplastic from non-neoplastic lesions by means of digital chromoendoscopy with magnification.

AUTHOR CONTRIBUTIONS

Santos CE, Pereira-Lima JC, Onofrio FQ were involved in subjects recruitment, data collection, interpretation of the results, provided assistance in statistical analyses and manuscript drafting. Moreira H, Ribas CA reviewed the manuscript, conceived and designed the study. Czezczko AE, Ramos RK, de Carvalho CA were involved in data collection, literature review and contributed to the results.

REFERENCES

1. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med*. 2012;366(8):687-96, <http://dx.doi.org/10.1056/NEJMoa1100370>.
2. Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, et al. Quality indicators for colonoscopy. *Gastrointest Endosc*. 2015;81(1):31-53, <http://dx.doi.org/10.1016/j.gie.2014.07.058>.
3. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol*. 2006;101(2):343-50, <http://dx.doi.org/10.1111/j.1572-0241.2006.00390.x>.
4. Heresbach D, Barrioz T, Lapalus MG, Coumaros D, Bauret P, Potier P, et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. *Endoscopy*. 2008;40(4):284-90, <http://dx.doi.org/10.1055/s-2007-995618>.
5. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology*. 2012;143(3):844-57, <http://dx.doi.org/10.1053/j.gastro.2012.06.001>.
6. dos Santos CE, Malaman D, Mönkemüller K, Dos Santos Carvalho T, Lopes CV, Pereira-Lima JC. Prevalence of non-polypoid colorectal neoplasms in southern Brazil. *Dig Endosc*. 2015;27(3):361-7, <http://dx.doi.org/10.1111/den.12346>.
7. Marmo R, Rotondano G, Riccio G, Marone A, Bianco MA, Stroppa I, et al. Effective bowel cleansing before colonoscopy: a randomized study of split-dosage versus non-split dosage regimens of high-volume versus low-volume polyethylene glycol solutions. *Gastrointest Endosc*. 2010;72(2):313-20, <http://dx.doi.org/10.1016/j.gie.2010.02.048>.



8. Menacho AM, Reimann A, Hirata LM, Ganzerella C, Ivano FH, Sugisawa R. Double-blind prospective randomized study comparing polyethylene glycol to lactulose for bowel preparation in colonoscopy. *Arq Bras Cir Dig*. 2014;27(1):9-12, <http://dx.doi.org/10.1590/S0102-67202014000100003>.
9. Lee RH, Tang RS, Muthusamy VR, Ho SB, Shah NK, Wetzel L, et al. Quality of colonoscopy with withdrawal technique and variability in adenoma detection rates (with videos). *Gastrointest Endosc*. 2011;74(1):128-34, <http://dx.doi.org/10.1016/j.gie.2011.03.003>.
10. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. *N Engl J Med*. 2006;355(24):2533-41, <http://dx.doi.org/10.1056/NEJMoa055498>.
11. Pickhardt PJ, Nugent PA, Mysliwiec PA, Choi JR, Schindler WR. Location of adenomas missed by optical colonoscopy. *Ann Intern Med*. 2004;141(5):352-9, <http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00009>.
12. Silva SM, Rosa VF, Santos AC, Almeida RM, Oliveira PG, Sousa JB. Influence of patient age and colorectal polyp size on histopathology findings. *Arq Bras Cir Dig*. 2014;27(2):109-13, <http://dx.doi.org/10.1590/S0102-67202014000200006>.
13. Rastogi A, Early DS, Gupta N, Bansal A, Singh V, Ansstas M, et al. Randomized, controlled trial of standard-definition white-light, high-definition white-light, and narrow-band imaging colonoscopy for the detection of colon polyps and prediction of polyp histology. *Gastrointest Endosc*. 2011;74(3):593-602, <http://dx.doi.org/10.1016/j.gie.2011.04.050>.
14. Pohl J, Schneider A, Vogell H, Mayer G, Kaiser G, Ell C. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. *Gut*. 2011;60(4):485-90, <http://dx.doi.org/10.1136/gut.2010.229534>.
15. Halpern Z, Gross SA, Gralnek IM, Shpak B, Pochapin M, Hoffman A, et al. Comparison of adenoma detection and miss rates between a novel balloon colonoscope and standard colonoscopy: a randomized tandem study. *Endoscopy*. 2015;47(3):238-44, <http://dx.doi.org/10.1055/s-0034-1391437>.
16. Leufkens AM, DeMarco DC, Rastogi A, Akerman PA, Azzouzi K, Rothstein RI, et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. *Gastrointest Endosc*. 2011;73(3):480-9, <http://dx.doi.org/10.1016/j.gie.2010.09.004>.
17. Gralnek IM, Siersema PD, Halpern Z, Segol O, Melhem A, Suissa A, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. *Lancet Oncol*. 2014;15(3):353-60, [http://dx.doi.org/10.1016/S1470-2045\(14\)70020-8](http://dx.doi.org/10.1016/S1470-2045(14)70020-8).
18. Leung FW, Amato A, Ell C, Friedland S, Harker JO, Hsieh YH, et al. Water-aided colonoscopy: a systematic review. *Gastrointest Endosc*. 2012;76(3):657-66, <http://dx.doi.org/10.1016/j.gie.2012.04.467>.
19. Chandran S, Parker F, Vaughan R, Mitchell B, Fanning S, Brown G, et al. Right-sided adenoma detection with retroflexion versus forward-view colonoscopy. *Gastrointest Endosc*. 2015;81(3):608-13, <http://dx.doi.org/10.1016/j.gie.2014.08.039>.
20. Rastogi A, Bansal A, Rao DS, Gupta N, Wani SB, Shipe T, et al. Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial. *Gut*. 2012;61(3):402-8, <http://dx.doi.org/10.1136/gutjnl-2011-300187>.
21. Biecker E, Floer M, Heinecke A, Ströbel P, Böhme R, Schepke M, et al. Novel endocuff-assisted colonoscopy significantly increases the polyp detection rate: a randomized controlled trial. *J Clin Gastroenterol*. 2015;49(5):413-8, <http://dx.doi.org/10.1097/MCG.0000000000000166>.
22. Dik VK, Gralnek IM, Segol O, Suissa A, Belderbos TD, Moons LM, et al. Multicenter, randomized, tandem evaluation of EndoRings colonoscopy – results of the CLEVER study. *Endoscopy*. 2015;47(12):1151-8, <http://dx.doi.org/10.1055/s-0034-1392421>.
23. Gutzeit A, Binkert CA, Koh DM, Hergan K, von Weymarn C, Graf N, et al. Evaluation of the anti-peristaltic effect of glucagon and hyoscine on the small bowel: comparison of intravenous and intramuscular drug administration. *Eur Radiol*. 2012;22(6):1186-94, <http://dx.doi.org/10.1007/s00330-011-2366-1>.
24. Cutler CS, Rex DK, Hawes RH, Lehman GA. Does routine intravenous glucagon administration facilitate colonoscopy? A randomized trial. *Gastrointest Endosc*. 1995;42(4):346-50, [http://dx.doi.org/10.1016/S0016-5107\(95\)70135-4](http://dx.doi.org/10.1016/S0016-5107(95)70135-4).
25. Waxman I, Mathews J, Gallagher J, Kidwell J, Collen MJ, Lewis JH, et al. Limited benefit of atropine as premedication for colonoscopy. *Gastrointest Endosc*. 1991;37(3):329-31, [http://dx.doi.org/10.1016/S0016-5107\(91\)70725-6](http://dx.doi.org/10.1016/S0016-5107(91)70725-6).
26. Souza MK, Jacob CE, Gama-Rodrigues J, Zilberstein B, Ceconello I, Habr-Gama A. The written informed consent form (WICF): factors that interfere with acceptance. *Arq Bras Cir Dig*. 2013;26(3):200-5, <http://dx.doi.org/10.1590/S0102-67202013000300009>.
27. BoehringerIngelheim. Buscopan 0807. August 22, 2008, <http://dx.doi.org/10.1016/j.gie.2011.12.010>.
28. Rondonotti E, Radaelli F, Paggi S, Amato A, Imperiali G, Terruzzi V, et al. Hyoscine N-butylbromide for adenoma detection during colonoscopy: a randomized, double-blind, placebo-controlled study. *Dig Liver Dis*. 2013;45(8):663-8, <http://dx.doi.org/10.1016/j.dld.2013.01.029>.
29. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. *Gastrointest Endosc*. 2003;58(6 suppl):S3-43.
30. Kudo Se, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, et al. Non-polypoid neoplastic lesions of the colorectal mucosa. *Gastrointest Endosc*. 2008;68(4 suppl):S3-47.
31. Teixeira CR, Torresini RS, Canali C, Figueiredo LF, Mucenic M, Pereira Lima JC, et al. Endoscopic classification of the capillary-vessel pattern of colorectal lesions by spectral estimation technology and magnifying imaging. *Gastrointest Endosc*. 2009;69(3 pt 2):750-6, <http://dx.doi.org/10.1016/j.gie.2008.09.062>.
32. Saunders BP, Williams CB. Premedication with intravenous antispasmodic speeds colonoscopy insertion. *Gastrointest Endosc*. 1996;43(3):209-11, [http://dx.doi.org/10.1016/S0016-5107\(96\)70317-6](http://dx.doi.org/10.1016/S0016-5107(96)70317-6).
33. Marshall JB, Patel M, Mahajan RJ, Early DS, King PD, Banerjee B. Benefit of intravenous antispasmodic (hyoscyamine sulfate) as premedication for colonoscopy. *Gastrointest Endosc*. 1999;49(6):720-6, [http://dx.doi.org/10.1016/S0016-5107\(99\)70289-0](http://dx.doi.org/10.1016/S0016-5107(99)70289-0).
34. East JE, Saunders BP, Burling D, Boone D, Halligan S, Taylor SA. Surface visualization at CT colonography simulated colonoscopy: effect of varying field of view and retrograde view. *Am J Gastroenterol*. 2007;102(11):2529-35, <http://dx.doi.org/10.1111/j.1572-0241.2007.01429.x>.
35. Yoong KY, Perkin D, Portal J, Strickland I, Heymann T. Intravenous hyoscine as a premedication for colonoscopy: a randomized double-blind controlled trial. *Endoscopy*. 2004;36(8):720-2, <http://dx.doi.org/10.1055/s-2004-825660>.
36. Mui LM, Ng EK, Chan KC, Ng CS, Yeung AC, Chan SK, et al. Randomized, double-blinded, placebo-controlled trial of intravenously administered hyoscine N-butyl bromide in patients undergoing colonoscopy with patient-controlled sedation. *Gastrointest Endosc*. 2004;59(1):22-7, [http://dx.doi.org/10.1016/S0016-5107\(03\)02377-0](http://dx.doi.org/10.1016/S0016-5107(03)02377-0).
37. Lee JM, Cheon JH, Park JJ, Moon CM, Kim ES, Kim TI, et al. Effects of Hyosine N-butyl bromide on the detection of polyps during colonoscopy. *Hepatogastroenterology*. 2010;57(97):90-4.
38. Rondonotti E, Zolk O, Amato A, Paggi S, Baccarin A, Spinzi G, et al. The impact of hyoscine-N-butylbromide on adenoma detection during colonoscopy: meta-analysis of randomized, controlled studies. *Gastrointest Endosc*. 2014;80(6):1103-12.e2, <http://dx.doi.org/10.1016/j.gie.2014.05.319>.
39. Cui PJ, Yao J, Han HZ, Zhao YJ, Yang J. Does hyoscine butylbromide really improve polyp detection during colonoscopy? A meta-analysis of randomized controlled trials. *World J Gastroenterol*. 2014;20(22):7034-9, <http://dx.doi.org/10.3748/wjg.v20.i22.7034>.
40. Corte C, Dahlenburg L, Selby W, Griffin S, Byrne C, Chua T, et al. Hyoscine butylbromide administered at the cecum increases polyp detection: a randomized double-blind placebo-controlled trial. *Endoscopy*. 2012;44(10):917-22, <http://dx.doi.org/10.1055/s-0032-1310009>.
41. de Brouwer EJ, Arbouw ME, van der Zwet WC, van Herwaarden MA, Ledeboer M, Jansman FG, et al. Hyoscine N-butylbromide does not improve polyp detection during colonoscopy: a double-blind, randomized, placebo-controlled, clinical trial. *Gastrointest Endosc*. 2012;75(4):835-40, <http://dx.doi.org/10.1016/j.gie.2011.12.010>.
42. Santos CE, Pereira-Lima JC, Lopes CV, Malaman D, Parada AA, Salomão AD. Comparative study between MBI (FICE) and magnification chromoendoscopy with indigo carmine in the differential diagnosis of neoplastic and non-neoplastic lesions of the colorectum. *Arq Gastroenterol*. 2009;46(2):111-5, <http://dx.doi.org/10.1590/S0004-28032009000200007>.
43. dos Santos CE, Lima JC, Lopes CV, Malaman D, Salomão AD, Garcia AC, et al. Computerized virtual chromoendoscopy versus indigo carmine chromoendoscopy combined with magnification for diagnosis of small colorectal lesions: a randomized and prospective study. *Eur J Gastroenterol Hepatol*. 2010;22(11):1364-71, <http://dx.doi.org/10.1097/MEG.0b013e32833a5d63>.
44. Dos Santos CE, Malaman D, Lopes CV, Pereira-Lima JC, Parada AA. Digital chromoendoscopy for diagnosis of diminutive colorectal lesions. *Diagn Ther Endosc*. 2012;2012:279521, <http://dx.doi.org/10.1155/2012/279521>.
45. Dos Santos CE, Perez HJ, Mönkemüller K, Malaman D, Lopes CV, Pereira-Lima JC. Observer agreement for diagnosis of colorectal lesions with analysis of the vascular pattern by image-enhanced endoscopy. *Endosc Int Open*. 2015;3(3):E240-5, <http://dx.doi.org/10.1055/s-0034-1391667>.
46. Japanese Society for Cancer of Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Tokyo: Kanehara Syuppan, 2010, <http://dx.doi.org/10.1007/s10147-011-0315-2>.